<DOC>
	<DOC>NCT00444925</DOC>
	<brief_summary>To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency &gt;= 8 per day and urgency urinary incontinence &gt;=1 per day Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention. Patients with significant hepatic and renal disease or other significant unstable diseases. OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>